Main menu
Edison Group
  • Home
  • Equities

    Equities

    View All Equities

    Equities by Sector

    VolitionRx

    MCap

    USD76m

    Last close

    USD0.81

    ▲ 0.14 (20.90%)

    Canyon Resources

    MCap

    AUD262m

    Last close

    AUD0.19

    ▲ 0.02 (12.12%)

    Immix Biopharma

    MCap

    USD51m

    Last close

    USD1.82

    ▲ 0.12 (7.06%)

  • Sectors

    Sectors

  • Thematics

    Thematics

    View All Thematics

    Latest

  • Audiovisual

    Audiovisual

    View All Audiovisual

    Latest

Ultimovacs (OSE: ULTI)

Last close As at 20/11/2024

NOK7.55

▲ 0.06 (0.80%)

Market capitalisation

260m

Edison Investment Research is terminating coverage on Ultimovacs (ULTI). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.

Latest Insights

View More

Healthcare | Flash note

Ultimovacs — Steadfast commitment to UV1 progression

Healthcare | Flash note

Ultimovacs — UV1 hits transitory roadblock with INITIUM top-line

Healthcare | Flash note

Ultimovacs — Peer-reviewed publication reiterates UV1’s potential

Healthcare | edison tv

Ultimovacs – executive interview
Ultimovacs_resized
Visit Website

Sector

Healthcare

Balance Sheet

Forecast net debt (NOKm)

N/A

Forecast gearing ratio (%)

N/A

Share Price Performance

Price Performance
% 1M 3M 12M
Actual 6.9 (93.9) (93.6)
Relative 5.1 (94.4) (94.3)
52 week high/low NOK160.4/NOK6.3

Financials

Edison Investment Research is terminating coverage on Oxford Cannabinoid Technologies (OCTP), Britvic (BVIC), Ultimovacs (ULTI), DFR Gold (DFR), The Merchants Trust (MRCH), PB Holding (PBH) and Biodexa Pharmaceuticals (BDRX). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.

Previously published reports can still be accessed via our website.

Y/E Dec Revenue (NOKm) EBITDA (NOKm) PBT (NOKm) EPS (fd) (öre) P/E (x) P/CF (x)
2022A 0.0 (181.0) (167.8) (489.9) N/A N/A
2023A 0.0 (213.0) (189.2) (550.1) N/A N/A
2024E N/A N/A N/A N/A N/A N/A
2025E N/A N/A N/A N/A N/A N/A

Research

Flash note

Healthcare

Ultimovacs — UV1 hits transitory roadblock with INITIUM top-line

Flash note

Healthcare

Ultimovacs — Peer-reviewed publication reiterates UV1’s potential

Healthcare

Flash note

Ultimovacs — Steadfast commitment to UV1 progression

edison tv

Healthcare

Ultimovacs – executive interview

Flash note

Healthcare

Ultimovacs — Another ODD boosts the off-the-shelf, universal UV1

Update

Healthcare

Ultimovacs — Universal approach with critical readouts in March
Ultimovacs_resized

Flash note

Healthcare

Ultimovacs — FDA Fast Track boosts confidence in UV1
Ultimovacs_resized

Flash note

Healthcare

Ultimovacs — INITIUM: March 2024 top-line timeline confirmed
Ultimovacs_resized

Flash note

Healthcare

Ultimovacs — TENDU results support TET platform expansion

edison tv

Healthcare

Ultimovacs – executive interview
Ultimovacs_resized

Update

Healthcare

Ultimovacs — Staying alive with UV1 in NIPU and INTIUM
View All

Thematics

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free